Claims
- 1. The compounds of formula I.
- 2. The compounds according to claim 1wherein: R1 is —CH3, —CH2CH3, —CH(CH3)2, or 20and R2 and R3 are H.
- 3. The compounds according to claim 1wherein: R1 is H or —CH2COOCH3; and R2 and R3 are independently H, or —CH2COOCH3, or —CH2COOH
- 4. The compounds according to claim 1wherein: R1 is H; and R2 and R3 are independently H or —CH2CO2H.
- 5. The compound according to claim 1 wherein R1, R2 and R3 are H.
- 6. The compound which has the structure:
- 7. A compound according to claim 1 selected from the group:
P175-A Methyl ester, P175-A Ethyl ester, P175-A Isopropyl ester, P175-A Benzyl ester, P175-A Ether A, P175-A Ether B, P175-A Ether C, P175-A Ether D, and P175-A Ether E.
- 8. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 1.
- 9. A pharmaceutical composition comprising an effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier.
- 10. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of the compound of claim 1 as an active ingredient.
- 11. A process for the preparation of antibiotic P175-A which comprises cultivating Micromonospora echinospora designated NRRL 30633 or a mutant thereof under aerobic conditions in a sterile liquid medium containing assimilable sources of carbon, nitrogen and inorganic anion and cation salts, until substantial antibiotic activity is imparted to said medium by the production of P175-A recovering and isolating said antibiotics.
- 12. A biologically pure culture of Micromonospora echinospora NRRL 30633 or a P175-A producing mutant thereof.
- 13. Antibiotic P175-A produced by the process which comprises aerobically fermenting the organism Micromonospora echinospora NRRL30633 or a mutant thereof in a liquid medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations until a substantial amount of said antibiotic P175-A is produced in said medium.
- 14. A process for the preparation of esters of P175-A having the structure
Parent Case Info
[0001] “This application claims priority from copending provisional application No. 60/467,612 filed May 2, 2003 the entire disclosure of which is hereby incorporated by reference”.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60467612 |
May 2003 |
US |